Please assess the completion status of the following clinical trial:

Trial Title: Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Subject is a female of at least 18 years of age~2. Subject has a diagnosis of symptomatic AVVC at baseline including a positive microscopic examination with 10% KOH in a vaginal sample revealing yeast forms (hyphae/pseudohyphae) or budding yeasts, and vaginal pH (≤4.5)~Key Exclusion Criteria:~1. Subject has any vaginal condition other than AVVC that may interfere with the diagnosis or evaluation of response to therapy, such as suspected or confirmed concurrent causes of vulvovaginitis and/or cervicitis (mixed infection)~2. Need for systemic and/or topical (vaginal) antifungal treatment, including prescription or over-the-counter products during the study and treatment for VVC 28 days prior to randomization~3. Subject is actively menstruating at the time of the Baseline visit.~4. Subject has uncontrolled diabetes mellitus.~5. Subject has a vaginal sample with pH \>4.5.~6. Subject has a history of or an active cervical/vaginal cancer.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluconazole (Type: ACTIVE_COMPARATOR): 150 mg/day for 1 day
- Ibrexafungerp 750mg (Type: EXPERIMENTAL): 750mg QD for 1 day only
- Ibrexafungerp 300mg (Type: EXPERIMENTAL): 300mg BID for 1 day only
- Ibrexafungerp 450mg (Type: EXPERIMENTAL): 450mg BID for 1 day only
- Ibrexafungerp 150mg (Type: EXPERIMENTAL): 150mg BID for 3 days
- Ibrexafungerp 300mg D1-D3 (Type: EXPERIMENTAL): 300mg BID for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).